KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) EBITDA Margin (2016 - 2026)

Edwards Lifesciences has reported EBITDA Margin over the past 17 years, most recently at 9.63% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1293.0% year-over-year to 9.63%; the TTM value through Dec 2025 reached 20.84%, down 451.0%, while the annual FY2025 figure was 20.84%, 451.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 9.63% at Edwards Lifesciences, down from 19.77% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 45.99% in Q4 2022 and troughed at 9.63% in Q4 2025.
  • A 5-year average of 28.32% and a median of 28.05% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 5774bps in 2021 and later plummeted -1860bps in 2023.
  • Year by year, EBITDA Margin stood at 28.16% in 2021, then soared by 63bps to 45.99% in 2022, then plummeted by -40bps to 27.38% in 2023, then decreased by -18bps to 22.56% in 2024, then crashed by -57bps to 9.63% in 2025.
  • Business Quant data shows EBITDA Margin for EW at 9.63% in Q4 2025, 19.77% in Q3 2025, and 26.84% in Q2 2025.